Yemaachi Biotechnology
YC S21Accra, GH · Founded 2020 · 16 employees · 8 known investors
Yemaachi creates a diverse cancer bio-database to develop oncology drugs effective across diverse patient populations. The company develops precision oncology research, diagnostics, and therapeutics with a focus on inclusion for global communities.
Also known as Yemaachi · Yemaachi Biotech
Founders & leadership· Y Combinator alumni (S21)
Yemaachi Biotechnology was founded in 2020 by Yaw Bediako, Yaw Attua-Afari, David Hutchful, and Joyce Ngoi.
Investors · 8
Also in the syndicate · 5
Company profile
researched Aug 2026Yemaachi Biotechnology is a precision oncology company headquartered in Accra, Ghana, that collects and sequences clinical and biological samples from populations across Africa to build what it describes as a first-of-its-kind pan-African clinical and molecular knowledgebase on cancer. The company's premise is that African populations are the most genetically diverse in the world yet are severely underrepresented in genetic studies, and that data from these populations can improve the global effectiveness of cancer diagnostics and therapeutics. It applies immunogenomics, bioinformatics, and artificial intelligence to this dataset to discover new diagnostic and therapeutic products, to optimize products developed by partner companies, and to support biomarker and drug discovery research.
Alongside its research and discovery work, Yemaachi offers accredited clinical next-generation-sequencing-based cancer screening and diagnostic testing services in Africa, positioned as affordable relative to existing options. Product and study activity described in sources includes the Sheba at-home HPV test launched in Ghana to identify women at high risk of cervical cancer, the AMBER Study conducted with Lucence using liquid biopsy to characterize breast cancer genetics in women of African heritage, and the PROGRESS project developed with Ghanaian paediatric oncologists to apply molecular tools to childhood leukaemia diagnosis and residual-disease monitoring. The company is the first institution in Ghana to operate an Oxford Nanopore PromethION 2 Solo sequencer, with stated plans to scale to a PromethION 24 so that samples no longer need to be sent abroad.
Founding story
Co-founder and CEO Yaw Bediako, an immunologist, initially intended to establish an academic research group in Ghana but found overseas philanthropic and government funding unsustainable and misaligned with local research priorities, including a Royal Society fellowship whose funding was cancelled after an eight-month application process. Observing that most research and development in Europe and North America occurs in the private sector, he concluded that African scientists would need to build African biotech themselves. The company's cancer focus was shaped in part by the death of his father from liver cancer, which led him to examine oncology and cancer outcomes in Africa. Yemaachi was founded with three co-founders — Yaw Attua-Afari, David Hutchful, and Joyce Ngoi — with the aim of improving precision oncology by leveraging Africa's genetic diversity.
Business model
Yemaachi combines a data and discovery business with clinical services. It builds a proprietary clinical and genomic cancer database from African samples and works with clinical, pharmaceutical, and biotech partners to discover and develop new diagnostic and therapeutic products or to optimize existing ones. In parallel it delivers accredited NGS-based cancer screening and diagnostic testing services, including the at-home Sheba HPV test in Ghana. Grant funding has also supported its work, including a $1 million Bill & Melinda Gates Foundation grant associated with the Calestous Juma Science Leadership Fellowship awarded to Bediako.
Revenue is derived from partnerships with clinical, pharmaceutical, and biotech organizations that use Yemaachi's database and analytics to discover, develop, or optimize diagnostic and therapeutic products, and from fee-based accredited clinical NGS screening and diagnostic testing services; grant funding supplements these sources.
Traction
The company was selected for Y Combinator's Summer 2021 batch and raised a $3 million seed round announced in March 2022. It launched the at-home Sheba HPV test in Ghana in January 2022, initiated the AMBER Study with Lucence, received a $1 million Bill & Melinda Gates Foundation grant tied to Bediako's Calestous Juma Science Leadership Fellowship, and installed Ghana's first PromethION 2 Solo sequencer. Reported team size ranges from 16 (Y Combinator) to 25 (Scispot case study).
Latest developments
A September 2025 post on the company's site highlighted an Oxford Nanopore Technologies interview with CEO Yaw Bediako covering the company's rationale for leveraging African genetic diversity for biomarker and drug discovery, its in-country sequencing capacity, and the PROGRESS paediatric leukaemia project with Ghanaian oncologists.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Yemaachi positions itself as an African-founded and Africa-based participant in precision oncology, addressing the underrepresentation of African ancestry in genomic databases and the relative scarcity of genetic testing services and cancer treatments on the continent. Sources describe its pan-African clinical and genomic cancer database as a first of its kind, and note that African-led research is intended to help build participant trust in genetic research given histories of exploitation of marginalised groups.
Differentiation rests on proprietary access to and sequencing of samples from African populations — described as the most genetically diverse on the planet, where rare alleles are detectable and small haplotype blocks aid causal variant identification in genome-wide association studies — combined with African-led operations intended to build community trust, in-country sequencing capacity that removes the need to ship samples abroad, and a team of scientists, engineers, and business operators with global expertise and African experience.
Technology
The company sequences samples from genetically diverse African populations and applies immunogenomics, bioinformatics, and artificial intelligence to the resulting clinical and molecular database. It operates Oxford Nanopore sequencing in-country, being the first institution in Ghana with a PromethION 2 Solo instrument and planning expansion to a PromethION 24. Diagnostic work includes next-generation-sequencing-based clinical screening and liquid biopsy approaches, the latter used in the AMBER breast cancer study with Lucence. To manage growing volumes of genomic and clinical data across distributed partners, Yemaachi uses the Scispot platform for clinical data recording, templated workflows, and automated sample and material tracking with chain-of-custody and regulatory compliance requirements.
Go-to-market
Yemaachi works through partnerships and collaborations with public, private, and non-profit organizations, including clinical, pharmaceutical, and biotech partners, academic and hospital collaborators such as Ghanaian paediatric oncologists, and technology suppliers; it also reaches patients directly with products such as the at-home Sheba HPV test and clinical diagnostic testing services.
Clinical, pharmaceutical, and biotech partners seeking diverse genomic data for biomarker discovery, drug development, and optimization of existing diagnostic tests; and patients and clinicians in Africa using its NGS-based cancer screening and diagnostic services, including women screened for cervical cancer risk via the Sheba HPV test and paediatric oncology patients addressed through the PROGRESS project.
Geography
Headquartered in Accra, Ghana (address listed as 222 Swaniker Street, Abelempke, Accra), with research and sample collection activity across Africa, including references to communities in Ghana and Kenya, and a global network of partners and collaborators across public, private, and non-profit sectors.
History
The company was founded in 2020 according to Y Combinator and StartupList Africa profiles, while the Oxford Nanopore interview and a related post on the company's site date the founding to 2021. It was selected for Y Combinator's Summer 2021 batch, announced a $3 million seed round in March 2022, and launched the Sheba at-home HPV test in Ghana in January 2022 while running the AMBER breast cancer study with Lucence and developing the PROGRESS paediatric oncology project.
Risks & controversies
Sources note structural challenges rather than company-specific controversies: community hesitancy to participate in genetic research stemming from historical exploitation of marginalised groups, dependence on external philanthropic or government research funding whose agendas and continuity can shift, local government prioritisation of infrastructure over research funding, and clinical challenges such as late diagnosis of childhood leukaemia in Africa.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 3
by search overlap
Companies competing with Yemaachi Biotechnology for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 7
launches, deals, and filingsYemaachi is described as the first institution in Ghana to have an Oxford Nanopore PromethION 2 Solo sequencer, with plans to scale up to a PromethION 24 to increase in-country sequencing capacity.
Yemaachi partnered with Scispot to templatize its workflows, record clinical data, and automate a digital Location Manager for sample and material tracking with chain-of-custody and regulatory compliance.
Yemaachi Biotech announced a $3 million seed round led by V8 Capital, with participation from LifeLine Family Heritage Fund, Y Combinator, Tencent, LoftyInc Capital, VestedWorld, V Square Capital, and Ethan Perlstein, to advance diversification of precision oncology.
$3M source ↗
The Bill and Melinda Gates Foundation awarded Yemaachi a $1 million grant as part of the Calestous Juma Science Leadership Fellowship awarded to co-founder and CEO Yaw Bediako.
$1M source ↗
The company launched its at-home Sheba HPV Test in Ghana to help identify women at high risk of cervical cancer, the second most frequent malignancy among women in West Africa.
Yemaachi Biotechnology was selected for Y Combinator's Summer 2021 batch.
Yemaachi and Lucence initiated the AMBER Study using liquid biopsy to better characterize and understand the genetics of breast cancer in women of African heritage.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 8
primary sources listed
- Yemaachi Biotechnologyyemaachi.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Yemaachi Biotechnology do?
- Ghana-based precision oncology company building a pan-African clinical and genomic cancer database for diagnostics and drug discovery.
- Who founded Yemaachi Biotechnology?
- Yemaachi Biotechnology was founded by Yaw Bediako, Yaw Attua-Afari, David Hutchful, Joyce Ngoi in 2020.
- Who are Yemaachi Biotechnology's investors?
- Yemaachi Biotechnology's investors include LoftyInc Capital, Y Combinator, First Circle.
- Where is Yemaachi Biotechnology headquartered?
- Yemaachi Biotechnology is headquartered in Accra, GH.